Skip to content

Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00194324
Enrollment
12
Registered
2005-09-19
Start date
2004-07-31
Completion date
2004-10-31
Last updated
2011-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health, Vulvovaginal Candidiasis

Brief summary

This study uses MRI to detect the spread of the Miconozole Nitrate OVULE within the vagina. The effect of moderate amounts of physical activity on the spread will be evaluated, and compared to no physical activity.

Interventions

PROCEDUREMagnetic resonance imaging
BEHAVIORALModerate levels of exercise

Sponsors

Johnson & Johnson
CollaboratorINDUSTRY
University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Not at risk for pregnancy * Willing to abstain from intercourse 24 hours prior to MRI * Regular menstrual cycles (every 23-38 days) * At least 10 weeks from most recent pregnancy outcome and had 2 spontaneous menstrual cycles since * Normal pap smear within previous 12 months * Negative test for yeast, bacterial vaginosis and trichomonas * Not allergic to any component of the formulation * No contraindications to MRI * Not participated in another investigational trial within 30 days * No history of condition, or finding on exam, that, in the opinion of the investigator, would make participation unsafe for the volunteer or complicate interpretation of the data

Design outcomes

Primary

MeasureTime frame
To compare between exercise and no exercise:
Time needed for the capsule to dissolve;
Quantify and describe product distribution at 20 minute intervals within the first 90 minutes after insertion;
Quantify systemic levels of miconozole nitrate 90 minutes and 24 hours after insertion;
Quantify amount of miconozole nitrate in the vagina 90 minutes and 24 hours after insertion

Secondary

MeasureTime frame
Presence bare spots in coating;
Product distribution will be assessed by:
Presence of product outside the introitus
Linear spread from the cervix covered by the product;
Percent of maximal linear spread from the cervix;
Surface area covered by the product;
Percent of maximal surface contact;

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026